Tsuruha Holdings Inc.

3391.T
Pharmaceutical Retailers
2026/04/09 Updated
Market Cap: $7.6B (¥1.2T)
Stock Price: $15.63 (¥2,490)
Exchange Rate: 1 USD = ¥159.24

Medium-Term Management Plan (Fiscal Year Ending February 2027 to Fiscal Year Ending February 2029)

Formulated a medium-term management plan from the fiscal year ending February 2027 to the fiscal year ending February 2029. The sales target for the fiscal year ending February 2029 is 2.7 trillion yen, EBITDA is 202.5 billion yen, and ROE is set at 7.0%.

Importance:
Page Updated: April 9, 2026
IR Disclosure Date: April 9, 2026

Key Figures

  • Net Sales Target (Fiscal Year Ending February 2029): 2.7 trillion yen
  • EBITDA Target (Fiscal Year Ending February 2029): 202.5 billion yen (7.5% margin)
  • ROE Target (Fiscal Year Ending February 2029): 7.0%

AI要約

Background and Vision of the Medium-Term Management Plan

In light of intensified competition and transformative phase in the drugstore market, leveraging our strengths of Japan's top store network, extensive product lineup, and customer data, we aim to evolve into a “customer-centric network” and create value as Japan's largest drugstore group. The construction of a value creation foundation toward realizing the vision of “LIFE STORE” is promoted as PHASE 1.

Numerical Targets and Strategies for the Fiscal Year Ending February 2029

Targets for the fiscal year ending February 2029 are net sales of 2.7 trillion yen, EBITDA of 202.5 billion yen (margin 7.5%), operating income of 135 billion yen (operating margin 5.0%), and ROE of 7.0%. In PHASE 1 (until February 2029), reforms will be promoted in multiple areas including qualitative transformation of the store network, enhancement of dispensing functions, restructuring and strengthening of private brands, promotion of DX, expansion of services, and strengthening overseas functions to build the foundation for value creation.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.